| 4.80 Data as of Jun 19 |  -0.01 / -0.21%Today’s Change | 1.41 Today|||52-Week Range 11.00 | +61.07% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $245.5M |
Company Description
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Its pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase inhibitors for the treatment of cancer. Its principal programs are directed toward gastroenterology, oncology and virology.The company has licensed development and commercialization rights for its first commercial product Relistor, for the treatment of opioid induced constipation. Progenics Pharmaceuticals was founded by Paul J. Maddon on December 1, 1986 and is headquartered in Tarrytown, NY.
Employees
Shareholders
| Mutual fund holders | 47.77% |
| Other institutional | 34.72% |
| Individual stakeholders | 3.26% |
Top Executives
| Mark Robert Baker | President, Chief Executive Officer & Director |
| Angelo William Lovallo, Jr., CPA | CFO, Treasurer, Chief Accounting Officer & VP |
| Robert J. Israel, MD | Senior VP-Medical Affairs & Clinical Research |
| William C. Olson, PhD | Senior Vice President-Research & Development |
| Kathleen Fredriksen | Director - Corporate Development |
.
